DK0768886T3 - Endothelforingseffekter og behandling af vasospastiske lidelser - Google Patents

Endothelforingseffekter og behandling af vasospastiske lidelser

Info

Publication number
DK0768886T3
DK0768886T3 DK96911890T DK96911890T DK0768886T3 DK 0768886 T3 DK0768886 T3 DK 0768886T3 DK 96911890 T DK96911890 T DK 96911890T DK 96911890 T DK96911890 T DK 96911890T DK 0768886 T3 DK0768886 T3 DK 0768886T3
Authority
DK
Denmark
Prior art keywords
patient
treatment
vasospastic disorders
endothelial lining
aliquot
Prior art date
Application number
DK96911890T
Other languages
English (en)
Inventor
Anthony Ernest Bolton
Ernest Davidson Cooke
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509197.1A external-priority patent/GB9509197D0/en
Priority claimed from GBGB9522475.4A external-priority patent/GB9522475D0/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DK0768886T3 publication Critical patent/DK0768886T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96911890T 1995-05-05 1996-05-03 Endothelforingseffekter og behandling af vasospastiske lidelser DK0768886T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9509197.1A GB9509197D0 (en) 1995-05-05 1995-05-05 Endothelial lining effects
GBGB9522475.4A GB9522475D0 (en) 1995-11-02 1995-11-02 Treatment of raynauds phenomenon
PCT/CA1996/000282 WO1996034613A1 (en) 1995-05-05 1996-05-03 Endothelial lining effects and treatment of vasospastic disorders

Publications (1)

Publication Number Publication Date
DK0768886T3 true DK0768886T3 (da) 2003-12-01

Family

ID=26306991

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96911890T DK0768886T3 (da) 1995-05-05 1996-05-03 Endothelforingseffekter og behandling af vasospastiske lidelser

Country Status (11)

Country Link
EP (1) EP0768886B1 (da)
JP (1) JPH10506636A (da)
AT (1) ATE246929T1 (da)
AU (1) AU721530B2 (da)
CA (1) CA2194485C (da)
DE (1) DE69629436T2 (da)
DK (1) DK0768886T3 (da)
ES (1) ES2205026T3 (da)
NZ (1) NZ306395A (da)
PT (1) PT768886E (da)
WO (1) WO1996034613A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2206180A1 (en) * 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
IL135014A0 (en) * 1997-09-12 2001-05-20 Vasogen Ireland Ltd A pharmaceutical composition for treating stress comprising pretreated blood
US6432399B1 (en) 1997-09-12 2002-08-13 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
IL144242A0 (en) * 1999-01-12 2002-05-23 Vasogen Ireland Ltd Pre-conditioning against cell death
CA2271190A1 (en) 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
EP1214037B1 (en) * 1999-09-16 2004-04-07 Vasogen Ireland Limited Apparatus for conditioning mammalian blood
US7125897B1 (en) 1999-09-24 2006-10-24 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
CA2309417A1 (en) 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
ES2280454T3 (es) * 1992-02-07 2007-09-16 Vasogen Ireland Limited Metodo para aumentar la concentracion de oxido nitrico en la sangre.
WO1993015778A1 (en) * 1992-02-07 1993-08-19 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
AU1524095A (en) * 1994-01-27 1995-08-15 Cellcor, Inc. Ex vivo activation of immune cells

Also Published As

Publication number Publication date
CA2194485C (en) 2001-09-18
CA2194485A1 (en) 1996-11-07
ATE246929T1 (de) 2003-08-15
EP0768886B1 (en) 2003-08-13
JPH10506636A (ja) 1998-06-30
WO1996034613A1 (en) 1996-11-07
EP0768886A1 (en) 1997-04-23
DE69629436T2 (de) 2004-06-17
AU721530B2 (en) 2000-07-06
AU5494496A (en) 1996-11-21
NZ306395A (en) 2000-02-28
PT768886E (pt) 2003-12-31
DE69629436D1 (de) 2003-09-18
ES2205026T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
ATE232396T1 (de) Oxydiertes thymosin beta 4
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE191506T1 (de) Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
DE69840913D1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK0661987T3 (da) Morphogeninduceret leverregeneration
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
FI801228A (fi) 6-substituerade 11-alkylen-morfantridiner foerfaranden foer deras framstaellning och terapeutiska medel innehaollande dessa
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
MX9206135A (es) Metodos
TR199901385T2 (xx) Piperidin t�revleri.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
DE69928407D1 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
ATE283063T1 (de) Allogene und xenogene transplantation
UA31903A (uk) Спосіб лікування хронічного неспецифічного простатиту